Broadcast ads need a brief summary or adequate provision for labeling access

AI-verifiedblockerBinding lawRaised as a question — a person decides

Rule

A broadcast advertisement for a prescription drug (other than an exempt reminder, bulk-sale-drug, or prescription-compounding-drug advertisement) must contain a brief summary of all necessary information related to side effects and contraindications, unless adequate provision is made for dissemination of the approved or permitted product labeling in connection with the broadcast presentation.

Check

First confirm the ad is a broadcast prescription-drug ad and not an exempt reminder, bulk-sale, or prescription-compounding ad. If a full brief summary of side effects/contraindications is not included in the broadcast, assess whether the accompanying provisions (e.g., referenced website, toll-free number, print piece, or other referral mechanism) reasonably ensure that the approved/permitted labeling is actually made available to the audience in connection with the broadcast; flag as a violation if neither a brief summary nor adequate provision for labeling access is present, or if the provision made is superficial or unlikely to result in effective dissemination.

Escalate when

Escalate when it is unclear whether the referral mechanism or access method used (e.g., adequacy of a website, phone line, or print supplement) constitutes "adequate provision" for dissemination of the labeling — this sufficiency judgment should be confirmed by a human reviewer, especially in borderline or novel format cases.

Where this comes from

21 CFR 202.1(e)(1)(i)(B). The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…ts. Advertisements broadcast through media such as radio, television, or telephone communications systems must: (A) Include information relating to the major side effects and contraindications (“major statement”) of the advertised drugs in the audio or audio and visual parts of the presentation, unless required by paragraph (e)(1)(ii)(C) of this section to present the major statement using audio and text; and (B) Contain a brief summary of all necessary information related to side effects and contraindications, unless adequate provision is made for dissemination of the approved or permitted product labeling in connection with the broadcast presentation. (ii) Human drug advertisements in television or radio format—Clear, conspicuous, and neutral manner. For advertisements for prescription drugs intended for use by humans presented directly to consumers in television or radio format, the major statement must be presented in a clear, conspicuous, and neutral manner. The major statement is presented in a clear, conspicuous, and neutral manner if the following are …

Open the original at these words on ecfr.gov ↗Read our full copy →

Document: 21 CFR 202.1
Version: 2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved: 2026-09-21 from www.ecfr.gov
Fingerprint: a542640a872b3f2702d549e8…

Applies when

Naturepromotional

Mediumbroadcast

Productdrug

Ad exemptionexcludes-reminder-adsexcludes-bulk-sale-drug-adsexcludes-prescription-compounding-drug-ads

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Supported: the quote is operative regulatory text from 21 CFR 202.1(e)(1)(i)(B), a 'must' directed at broadcast advertisements, not an example, definition, or description of what is not required. The rule statement tracks the provision's brief-summary/adequate-provision disjunction faithfully.
- Authority 'binding' is correct: this is a codified FDA regulation under 21 CFR, not guidance.
- Locator is correct and precise: the quoted sentence is verbatim subparagraph (e)(1)(i)(B), and the source text confirms the surrounding (e)(1)(i) 'Broadcast advertisements' heading covering radio, television, and telephone communications systems.
- Severity 'blocker' is defensible: an ad lacking both a brief summary and adequate provision fails a mandatory requirement of the advertising regulation.
- Atomic: a single obligation with an integral 'unless' exception; the exception is not an independently checkable second requirement.
- Determinism is wrong. The escape clause turns on whether 'adequate provision is made' for dissemination of labeling. Adequacy is a sufficiency assessment, not a presence/absence or literal-match test. The rule's own check ('verify adequate provision ... is made') concedes this.
- Overstated on scope, omission 1: Section 202.1 by its opening sentence governs prescription-drug advertisements only, but applies_when reaches any promotional broadcast material with no drug-class limit.
- Overstated on scope, omission 2: Section 202.1(e)(2) exempts reminder advertisements, bulk-sale drug advertisements, and prescription-compounding drug advertisements from all of paragraph (e)(1). As written the rule would flag a broadcast reminder ad as a blocker, which the source affirmatively excludes.
- Minor fidelity issue: the rule paraphrases the exception as adequate provision for 'consumers' to access labeling, but the regulation says 'dissemination of the approved or permitted product labeling' with no audience limitation; the consumer-directed requirements sit in (e)(1)(ii), a different subparagraph.
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — pass
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Supported: the quote is the operative text of §202.1(e)(1)(i)(B), an affirmative 'must' requirement in the regulatory text itself — not an example, definition, or preamble. The chapeau at (e)(1)(i) ('Advertisements broadcast through media such as radio, television, or telephone communications systems must:') supplies the 'must' that the rule statement carries over verbatim.
- Not overstated: the rule reproduces the obligation and its 'unless adequate provision' escape clause without hardening it, and does not convert the conditional into an absolute brief-summary mandate. Scope is correctly held to broadcast media and to prescription drugs, matching §202.1's opening definition and (e)(1)'s 'All advertisements for any prescription drug'.
- applies_when is justified rather than invented: the three ad-exemption exclusions (reminder, bulk-sale drug, prescription-compounding drug) map exactly to §202.1(e)(2)(i)-(iii), which the source states are 'exempt from the requirements of paragraph (e)(1)'. The obvious limits (broadcast medium, prescription drug) are present rather than missing.
- Atomic: a single obligation with a built-in statutory alternative. The brief summary and the adequate-provision alternative are two routes to satisfying one requirement, not two independently checkable requirements — a reviewer reaches one finding. Note the rule correctly does not also bundle in the separate (A) 'major statement' duty, which is a distinct requirement.
- determinism 'judgment' is right: 'all necessary information' and especially 'adequate provision' turn on sufficiency and effectiveness of dissemination, which cannot be settled by presence/absence or literal match. The escalate-when clause correctly targets precisely that sufficiency call.
- authority 'binding' is right: 21 CFR 202.1 is a codified regulation, and the cited language is mandatory ('must'), not guidance.
- Locator 21 CFR 202.1(e)(1)(i)(B) is exact — the quoted sentence appears at that subparagraph in the source text.
- Severity 'blocker' is defensible: absence of both the brief summary and adequate provision renders the broadcast ad non-compliant with a binding FDA regulation and, under section 502(n), misbranding exposure; it is not a stylistic defect that can ship.
- Minor, not blocking: applies_when product-type is the broad value 'drug' while the regulation reaches only prescription drugs, but the rule statement and check both state 'prescription drug', so the constraint is not lost. Similarly, the (e)(2) exemptions are conditional (e.g., reminder-ad exemption is unavailable for boxed-warning products and can be withdrawn by the Commissioner); the rule's shorthand 'exempt reminder ... advertisement' fairly carries that conditionality since only a qualifying reminder ad is exempt.